New Delhi : NIPER Hajipur has signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim India to strengthen pharmaceutical research collaboration and accelerate innovation in India’s healthcare sector.
The agreement was formalized at Kartavya Bhawan in New Delhi in the presence of Manoj Joshi, highlighting the government’s continued support for industry–academia partnerships.
Expanding Industry–Academia Collaboration
The partnership aims to deepen engagement between academia and industry by fostering joint research initiatives, facilitating knowledge exchange, and enhancing capacity building in advanced pharmaceutical sciences.
As part of the collaboration, Boehringer Ingelheim India will provide access to its opnMe® open science platform—an initiative designed to promote global scientific collaboration and support early-stage drug discovery research.
Driving Translational Research and Drug Development
The MoU is expected to significantly strengthen research capabilities at NIPER Hajipur by focusing on translational science and innovation. Key areas of collaboration include:
- Hands-on training opportunities for students and researchers
- Support for early-stage proof-of-concept studies
- Advancement of translational pharmacology research
- Faster transition from laboratory discoveries to preclinical development
By integrating academic research with industry expertise, the initiative aims to create a more efficient and outcome-driven research ecosystem.
Government Push for Innovation Ecosystem
Officials at the signing ceremony emphasized the critical role of such collaborations in bridging the gap between academic research and commercial drug development.
The partnership aligns with India’s broader vision of building a robust, innovation-led pharmaceutical ecosystem capable of competing globally in drug discovery and healthcare research.
Strengthening India’s Global Pharma Position
This collaboration is expected to position NIPER Hajipur as a key hub for translational pharmaceutical research while reinforcing India’s growing role in global healthcare innovation networks.
By combining scientific expertise from academia with industrial capabilities, the partnership aims to accelerate the development of next-generation therapies to address emerging healthcare challenges.